Pomeranian Medical University — Clinical Trial Site

14 Registered trials

9 Currently recruiting

Organisation

Pomeranian Medical University

Location

Szczecin, Poland

Identifier

ORG-100016434

Address

Ul. Unii Lubelskiej 1, 71-252, Poland

Departments

4112
Centrum Wsparcia Badań Klinicznych
Centrum Wsparcia Badań Klinicznych Pomorskiego Uniwersytetu Medycznego (CWBK PUM)
Centrum Wsparcia Badan Klinicznych Pomorskiego Uniwersytetu Medycznego w Szczecinie
Centrum Wsparcia Badan Klinicznych PUM
Department of Paediatrics, Oncology and Paediatric Immunology
Klinika Chorób Wewnętrznych, Reumatologii, Diabetologii, Geriatrii i Immunologii
N/A
Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of the Development Age

Clinical trials at this site (14)

Search interface

A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Tr… Not authorised

2025-523820-26-00 Growth Hormone Deficiency (GHD) 5
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting

2025-524366-21-00 treatment-naive Chronic Lymphocytic Leukemia 5 2026-04-29
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A Phase 3 Study of JNT-517 in Participants with Phenylketonuria Recruiting

2024-519554-37-00 Phenylketonuria 5 2026-01-16
A study of sepiapterin in participants with phenylketonuria (PKU) (EPIPHENY) Recruiting

2024-514435-20-00 Phenylketonuria 5 2025-12-23
"A research study comparing different doses of CDR132L with placebo on the structure and function of the heart in people with heart failure … Recruiting

2024-515796-35-00 Heart Failure with Preserved Ejection Fraction and Left 4 2025-06-26
A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced/mildly … Recruiting

2024-515797-27-00 Heart Failure with Reduced/Mildly Reducede Ejection Fra 4 2025-06-25
An open-label, pharmacokinetic, safety, and efficacy study (Part I, single cycle) and double-blind, efficacy, non inferiority, and safety st… Recruiting

2024-514321-39-00 Chemotherapy-induced nausea and vomiting 10 2025-05-06
Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome Recruiting

2024-516919-25-00 SAPHO syndrome (synovitis, acne, pustulosis, hyperostos 10 2024-10-22
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended

2022-500700-22-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-25
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria Ended

2023-509229-31-00 Metabolic Disorders - Phenylketonuria 5 2022-09-28
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Bas… Ended

2024-516662-11-00 Ovarian epithelial cancer 5 2018-11-23
A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin versus Sapropterin in Participants With Phenylketonuria… Ended

2023-506238-61-00 Phenylketonuria 5 2024-05-10